FIELD: medicine.
SUBSTANCE: invention relates to field of medicine, in particular to hepatology, and can be used for prediction of fast virological response to therapy with pegylated interferon α and ribavirin in patients with chronic hepatitis C. For this purpose allele version of IL28B gene is identified and immunological assay is carried out. In case of presence of allele rs12979860CC/rs8099917TT immunoprediction coefficient 1 (IPC-1) is calculated by formula: IPC-1=2.774-0.833*[CD3+]-0.016*[CD4+]-0.063*[CD8+]-0.525*[CD19+], where [CD3+] is absolute content of CD3+ cells in 1 l of blood, [CD4+] is absolute content of CD3+/CD4+ cells in 1 l of blood, [CD8+] is absolute content of CD3+/CD8+ cells in 1 l of blood, [CD19+] is absolute content of CD19+ cells in 1 l of blood. If IPC-1 value is ≤1,5 development of fast virological response to standard therapy is predicted, in case of IPC-1>1.5 - its absence. If any other allele version is present IPC-2 is calculated by formula: IPC-2=3.994+0.014*[CD56+/ki-67+]-0.408*[CD25hi]-0.69*[CD25hi/FoxP3+], where [CD56+/ki-67+] is % of CD16+/CD56+/ki-67+ cells among blood lymphocytes, [CD25hi] is % of CD3+/CD25high cells among blood lymphocytes, [CD25hi/FoxP3+] is % of CD3+/CD25high/FoxP3+ cells among blood lymphocytes. If IPC-2 value is ≤3.0, fast development of fast virological response to standard therapy is predicted, in case of IPC-2 value >3.0 - its absence.
EFFECT: application of claimed method makes it possible to identify different shifts of immunograms by different allele versions of IL28B gene and provides possibility to predict presence or absence of fast virological response.
5 dwg, 2 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTION OF EFFICACY OF ANTIVIRAL THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1b | 2012 |
|
RU2522500C1 |
METHOD FOR PREDICTING THE ABSENCE OF REGRESS OF HEPATIC FIBROSIS IN THE PATIENTS WITH CHRONIC HEPATITIS C | 2019 |
|
RU2723387C1 |
DIAGNOSTIC TECHNIQUE FOR HEPATIC CIRRHOSIS (STAGE F4) IN THE OUTCOME OF CHRONIC VIRAL HEPATITIS C | 2019 |
|
RU2724595C1 |
METHOD FOR PREDICTION OF EFFICACY OF ANTIVIRAL TREATMENT OF CHRONIC VIRAL HEPATITIS C | 2013 |
|
RU2546032C2 |
METHOD FOR INDIVIDUAL PREDICTION OF THERAPEUTIC EFFICACY OF CHRONIC HEPATITIS C WITH PEGYLATED INTERFERON ALPHA AND RIBAVIRIN | 2013 |
|
RU2525159C1 |
PREDICTION OF KINETICS OF HEPATITIS C VIRUS IN INTERFERON-EXCLUDING TREATMENT | 2011 |
|
RU2590691C2 |
METHOD FOR PREDICTING THE EFFICIENCY OF TREATMENT OF HEPATITIS C WITH THE CHILDREN OF THE FIRST YEAR OF LIFE | 2016 |
|
RU2646510C1 |
METHOD FOR PREDICTION OF LIVER FIBROSIS DYNAMICS IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1, NOT RESPONDING TO TREATMENT WITH PEGYLATED INTERFERONS AND RIBAVIRIN | 2015 |
|
RU2623151C2 |
METHOD FOR PREDICTION OF RELIABILITY OF RESPONSE TO ROUTINE TWO-COMPONENT ANTIRETROVIRAL THERAPY WITH PEGYLATED INTERFERONS AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1B | 2014 |
|
RU2578030C2 |
METHOD OF HEPATIC FIBROSIS ASSESSMENT IN PATIENTS WITH CHRONIC VIRAL HEPATITIS TYPE C | 2009 |
|
RU2416794C1 |
Authors
Dates
2015-09-20—Published
2013-10-09—Filed